Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent (Development Code TCD-10023) With Biodegradable Polymer at 1, 2 and 3 Months
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2018
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Myocardial infarction; Thrombosis; Venous thromboembolism
- Focus Registrational; Therapeutic Use
- Acronyms DISCOVERY123
- Sponsors Terumo
- 03 Jul 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
- 03 Jul 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2016.
- 11 May 2015 Planned End Date changed from 1 Jan 2016 to 1 Mar 2016, according to to ClinicalTrials.gov record.